Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry
| Autor: | Sagrario Galiano Mejías, Victoria Mendiola-Fernández, F.J. Gómez-García, Gregorio Carretero, Beatriz Pérez Zafrilla, Pablo De la Cueva-Dobao, P. Dávila-Seijo, Cristina Sánchez Roldán, Raquel Rivera, D P Ruiz-Genao, Enrique Herrera-Ceballos, Carlos Ferrándiz, Miguel Ángel Descalzo, Carlos Muñoz-Santos, Francisco Vanaclocha, R. Torrado, E. Daudén, R. Jiménez-Puya, José Manuel Carrascosa, Marta Ferran, Begoña Echeverría, Mar Llamas, Isabel Belinchón, Ignacio García-Doval, Mercè Alsina, J.L. Sánchez-Carazo, José Luis López-Estebaranz |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male medicine.medical_specialty Dermatology Biochemistry Etanercept 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Internal medicine Psoriasis Ustekinumab Adalimumab medicine Humans Poisson Distribution Registries Adverse effect Molecular Biology Aged 030203 arthritis & rheumatology Biological Products business.industry Cell Biology Bacterial Infections Middle Aged medicine.disease Infliximab Surgery Methotrexate Relative risk Cyclosporine Drug Therapy Combination Female business medicine.drug |
| Zdroj: | JOURNAL OF INVESTIGATIVE DERMATOLOGY r-FISABIO. Repositorio Institucional de Producción Científica instname r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante r-FISABIO: Repositorio Institucional de Producción Científica Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
| ISSN: | 1523-1747 0022-202X |
| Popis: | Information regarding the safety of biological drugs prescribed to psoriasis patients on daily and long-term bases is insufficient. We used data from the BIOBADADERM registry (Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases) to generate crude rates of infection during therapy with systemic drugs, including biological drugs (infliximab, etanercept, adalimumab, and ustekinumab) and nonbiological drugs (acitretin, cyclosporine, and methotrexate). We also calculated unadjusted and adjusted risk ratios (RRs) (with propensity score adjustment) of infection, serious infections, and recurrent infections of systemic therapies compared with methotrexate, using Poisson regression. Our study included records of 2,153 patients (7,867.5 person-years). The adjusted RR of overall infection was significantly increased in the groups treated with adalimumab with methotrexate (adjusted RR = 2.13, 95% confidence interval [CI] = 1.2-3.7), infliximab (adjusted RR = 1.71, 95% CI = 1.1-2.65), cyclosporine (adjusted RR = 1.58, 95% CI = 1.17-2.15), ustekinumab with methotrexate (adjusted RR = 1.56, 95% CI = 1.08-2.25), and etanercept (adjusted RR = 1.34, 95% CI: 1.02-1.76) compared with methotrexate alone. Cyclosporine had a significant risk of serious infection (adjusted RR = 3.12, 95% CI = 1.1-8.8), followed by adalimumab combined with methotrexate (adjusted RR = 3.28, 95% CI = 0.8-13.5). Adalimumab in combination with methotrexate had the highest risk of infection recurrence (adjusted RR = 4.33, 95% CI = 2.27-8.24). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|